Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.

Cunningham, D; Hawkes, E; Jack, A; Qian, W; Smith, P; Mouncey, P; Pocock, C; Ardeshna, K; Radford, John A; McMillan, A; Davies, J; Turner, D; Kruger, A; Johnson, P; Gambell, J; Linch, D

dc.contributor.author	Cunningham, D
dc.contributor.author	Hawkes, E
dc.contributor.author	Jack, A
dc.contributor.author	Qian, W
dc.contributor.author	Smith, P
dc.contributor.author	Mouncey, P
dc.contributor.author	Pocock, C
dc.contributor.author	Ardeshna, K
dc.contributor.author	Radford, John A
dc.contributor.author	McMillan, A
dc.contributor.author	Davies, J
dc.contributor.author	Turner, D
dc.contributor.author	Kruger, A
dc.contributor.author	Johnson, P
dc.contributor.author	Gambell, J
dc.contributor.author	Linch, D
dc.date.accessioned	2013-08-05T13:36:44Z
dc.date.available	2013-08-05T13:36:44Z
dc.date.issued	2013-05-25
dc.identifier.citation	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. 2013, 381 (9880):1817-26 Lancet	en_GB
dc.identifier.issn	1474-547X
dc.identifier.pmid	23615461
dc.identifier.doi	10.1016/S0140-6736(13)60313-X
dc.identifier.uri	http://hdl.handle.net/10541/297415
dc.description.abstract	Dose intensification with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) every 2 weeks improves outcomes in patients older than 60 years with diffuse large B-cell lymphoma compared with CHOP every 3 weeks. We investigated whether this survival benefit from dose intensification persists in the presence of rituximab (R-CHOP) in all age groups.
dc.language.iso	en	en
dc.rights	Archived with thanks to Lancet	en_GB
dc.subject.mesh	Adult
dc.subject.mesh	Aged
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Antibodies, Monoclonal, Murine-Derived
dc.subject.mesh	Antineoplastic Combined Chemotherapy Protocols
dc.subject.mesh	Cyclophosphamide
dc.subject.mesh	Disease-Free Survival
dc.subject.mesh	Dose-Response Relationship, Drug
dc.subject.mesh	Doxorubicin
dc.subject.mesh	Drug Administration Schedule
dc.subject.mesh	Female
dc.subject.mesh	Humans
dc.subject.mesh	Lymphoma, Large B-Cell, Diffuse
dc.subject.mesh	Male
dc.subject.mesh	Middle Aged
dc.subject.mesh	Prednisone
dc.subject.mesh	Treatment Outcome
dc.subject.mesh	Vincristine
dc.title	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.	en
dc.type	Article	en
dc.contributor.department	Royal Marsden NHS Foundation Trust, London and Surrey, UK. david.cunningham@rmh.nhs.uk	en_GB
dc.identifier.journal	Lancet	en_GB
refterms.dateFOA	2020-04-27T13:15:17Z
html.description.abstract	Dose intensification with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) every 2 weeks improves outcomes in patients older than 60 years with diffuse large B-cell lymphoma compared with CHOP every 3 weeks. We investigated whether this survival benefit from dose intensification persists in the presence of rituximab (R-CHOP) in all age groups.